Hyaluronic acid coated poly-ε-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea

Experimental Eye Research

Volumn 87, Issue 3, 2008, Pages 162-167

  Yenice, Irem ^a   Mocan, Mehmet C ^a   Palaska, Erhan ^a   Bochot, Amélie ^b   Bilensoy, Erem ^a   Vural, Imran ^a   Irkeç, Murat ^a   Atilla Hincal, A ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIV PARIS SUD   (France)

Author keywords

benzalkonium chloride; cornea; cyclosporine A; hyaluronic acid; nanoparticles; ocular distribution

Indexed keywords

BENZALKONIUM CHLORIDE; CASTOR OIL; CYCLOSPORIN A; HYALURONIC ACID; NANOSPHERE; POLYCAPROLACTONE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; CORNEA; DRUG BIOAVAILABILITY; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL AVAILABILITY; CORNEA; CYCLOSPORINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEXANOIC ACIDS; HYALURONIC ACID; IMMUNOSUPPRESSIVE AGENTS; LACTONES; MALE; NANOSPHERES; OPHTHALMIC SOLUTIONS; RABBITS; TEARS;

EID: 50849099475     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.04.002     Document Type: Article

References (39)

1. Akpek E.K., Dart J.K., Watson S., Christen W., Dursun D., Yoo S., O'Brien T.P., Schein O.D., and Gottsch J.D. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 111 (2004) 476-482
2. Algros M.P., Angonin R., and Delbose B. Danger of systemic cyclosporine for corneal graft. Cornea 21 (2002) 613-614
3. Barbault-Foucher S., Gref R., Russo P., Guechot J., and Bochot A. Design of poly-epsilon-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J. Control. Rel. 83 (2002) 365-375
4. Behrens-Baumann W., Theuring S., and Brewitt H. The effect of topical cyclosporin A on rabbit cornea: a clinical and electron microscope study. Graefes Arch. Clin. Exp. Ophthalmol. 224 (1986) 520-524
5. Belin W.M., Bouchard C.S., and Phillips T.M. Update on topical cyclosporin A, background, immunology and pharmacology. Cornea 9 (1990) 184-195
6. BenEzra D., and Maftzir G. Ocular penetration of cyclosporin A. Invest. Ophthalmol. Vis. Sci. 31 (1990) 1362-1366
7. BenEzra D., Maftzir G., de Courten C., and Timonen P. Ocular penetration of cyclosporin A. III: the human eye. Br. J. Ophthalmol. 74 (1990) 350-352
8. Calvo P., Sanchez A., Martinez J., Lopez M.I., Calonge M., Pastor J.C., and Alonso M.J. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm. Res. 13 (1996) 311-315
9. Cha S.-H., Lee J.-S., Oum B.-S., and Kim C.-D. Corneal epithelial cellular dysfunction from benzalkonium chloride (BKC) in vitro. Clin. Exp. Ophthalmol. 32 (2004) 180-184
10. De Campos A.M., Sánchez A., and Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224 (2001) 159-168
11. Debbasch C., Brignole F., Pisella P.-J., Warnet J.-M., Rat P., and Baudouin C. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 42 (2001) 642-652
12. Debbasch C., Pisella P.-J., De Saint Jean M., Rat P., Warnet J.-M., and Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved β-blockers on chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2525-2533
13. Debbasch C., De La Salle S.B., Brignole F., Rat P., Warnet J.-M., and Baudouin C. Cytoprotective effects of hyaluronic acid and carbomer 934P in ocular surface epithelial cells. Invest. Ophthalmol. Vis. Sci. 43 (2002) 3409-3415
14. Durrani A.M., Farr S.J., and Kellaway I.W. Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye. Int. J. Pharm. 118 (1995) 243-250
15. Fahr A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24 (1993) 472-495
16. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., and Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55 (1989) R1-R4
17. Gupta V., and Sahu K.P. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye 15 (2001) 39-41
18. Harper III C.A., Khoobehi B., Peyman G.A., Genhardt B.M., and Dunlap W.A. Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits. Int. Ophthalmol. 17 (1993) 337-340
19. Kanai A., et al. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant. Proc. 21 (1989) 3150-3152
20. Kanpolat A., Batioglu F., Yilmaz M., and Akbas F. Penetration of cyclosporin A into the rabbit cornea and aqueous humor after topical drop and collagen shield administration. CLAO J 20 (1994) 119-122
21. Kaswan R.L. Intraocular penetration of topically applied cyclosporine. Transplant. Proc. 20 Suppl. 2 (1988) 650-655 (2)
22. Kuwano M., Ibuki H., Morikawa N., Ota A., and Kawashima Y. Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm. Res. 19 (2002) 108-111
23. Lallemand F., Felt-Baeyens O., Besseghir K., Behar-Cohen F., and Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur. J. Pharm. Biopharm. 56 (2003) 307-318
24. Lallemand F., Furner F., Felt-Baeyens O., Gex-Fabry M., Dumant J.M., Besseghir K., and Gurny R. A novel water soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics. Int. J. Pharm. 295 (2005) 7-14
25. Nussenblatt R.B., and Paletsine A.G. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv. Ophthalmol. 31 (1986) 159-169
26. Oh C., Saville B.A., Cheng Y.-L., and Rootman D.S. Compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits. Pharm. Res. 12 (1995) 433-437
27. Petcher T.J., Weder H.P., and Rüegger A. Crystal and molecular structure of an iodo derivative of the cyclic undecapeptide cyclosporin A. Helv. Chim. Acta 59 (1976) 1480-1488
28. Robert P.Y., Leconte V., Olivé R., Javerliat M., and Adenis J.-P. Collyre à la cyclosporine a: fabrication, toxicité, pharmacocinétique et indications en l'an 2000. J. Fr. Ophtalmol. 24 (2001) 527-535
29. Rumelt S., Bersudsky V., Blum-Hareuveni T., and Rehany U. Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br. J. Ophthalmol. 86 (2002) 988-992
30. Sasamoto Y., Hirose S., Ohno S., Onoé K., and Matsuda H. Topical application of ciclosporin ophtalmic solution containing alpha-cyclodextrin in experimental uveitis. Ophthalmologica 203 (1991) 118-125
31. Small D., Hevy J., and Tang-Liu D. Comparison of tear sampling techniques for pharmacokinetic analysis: ofloxocin concentrations in rabbit tears after sampling with schirmer tear strips, capillary tubes, or surgical sponges. J. Ocul. Pharm. Ther. 16 (2000) 439-446
32. Tang-Liu D.D.-S., and Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin. Pharmacokinet. 44 (2005) 247-261
33. Taylor P.J. Therapeutic drug monitoring of immunosuppressant drugs by high performance liquid chromatography-mass spectrometry. Ther. Drug Monit. 26 (2004) 215-219
34. Theng J., Zhou L., Tan D., and Lam K.-W. Distribution of cyclosporin A in the cornea after topical and oral administration. J. Ocul. Pharm. Ther. 18 (2002) 83-88
35. Van der Bijl P., van Eyk A.D., and Meyer D. Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea 20 (2001) 505-508
36. Vernillet L., Lundh R.L., Acezat-Mispelter F., Goizel C., Humbert H., and Pouliquen Y. Ocular distribution of cyclosporin A (sandimmun™) following systemic and topical administration to rabbits. Eur. J. Drug Metab. Pharmacokinet. 3 (1991) 150-158
37. Wiederholt M., Kossendrup D., Schultz W., and Hoffmann F. Pharmacokinetics of topical cyclosporin A in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 27 (1986) 519-524
38. Yuan H., Yuling L., Yu L., Jiancheng W., Xuan Z., Wanliang L., Zhizhong M., Xiuan Z., and Qiang Z. Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. Invest. Ophthalmol. Vis. Sci. 47 (2006) 3983-3988
39. Zhou L., Tan D., Theng J., Lim L., Li Y.-P., and Lam K.-W. Optimized analytical metod for cyclosporin A by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B. 754 (2001) 201-207